Viewing Study NCT04923906


Ignite Creation Date: 2025-12-26 @ 5:17 PM
Ignite Modification Date: 2026-04-25 @ 3:23 PM
Study NCT ID: NCT04923906
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-11-25
First Post: 2021-06-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Concurrent Chemotherapy, Aumolertinib, EGFR-TKI, EGFRm+, Ex19Del, L858R, HS-10296, Stage IIIB-IV, … View